 Apolipoprotein C-III
"Apolipoprotein C-III" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 9-kDa protein component of VERY-LOW-DENSITY LIPOPROTEINS and CHYLOMICRON REMNANTS. Apo C-III, synthesized in the liver, is an inhibitor of LIPOPROTEIN LIPASE. Apo C-III modulates the binding of chylomicron remnants and VLDL to receptors (RECEPTORS, LDL) thus decreases the uptake of triglyceride-rich particles by the liver cells and subsequent degradation. The normal Apo C-III is glycosylated. There are several polymorphic forms with varying amounts of SIALIC ACID (Apo C-III-0, Apo C-III-1, and Apo C-III-2).
| Descriptor ID |
D053305
|
| MeSH Number(s) |
D10.532.091.400.875 D12.776.070.400.400.875 D12.776.521.120.400.875
|
| Concept/Terms |
Sialyl Apo C-III- Sialyl Apo C-III
- Apo C-III, Sialyl
- Sialyl Apo C III
- Sialyl Apolipoprotein C-III
- Apolipoprotein C-III, Sialyl
- Sialyl Apolipoprotein C III
|
Below are MeSH descriptors whose meaning is more general than "Apolipoprotein C-III".
Below are MeSH descriptors whose meaning is more specific than "Apolipoprotein C-III".
This graph shows the total number of publications written about "Apolipoprotein C-III" by people in this website by year, and whether "Apolipoprotein C-III" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 2 | 2 | | 2009 | 1 | 0 | 1 | | 2013 | 0 | 1 | 1 | | 2019 | 0 | 1 | 1 | | 2023 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Apolipoprotein C-III" by people in Profiles.
-
Hsu CC, Shao B, Kanter JE, He Y, Vaisar T, Witztum JL, Snell-Bergeon J, McInnes G, Bruse S, Gottesman O, Mullick AE, Bornfeldt KE. Apolipoprotein C3 induces inflammasome activation only in its delipidated form. Nat Immunol. 2023 03; 24(3):408-411.
-
Kanter JE, Shao B, Kramer F, Barnhart S, Shimizu-Albergine M, Vaisar T, Graham MJ, Crooke RM, Manuel CR, Haeusler RA, Mar D, Bomsztyk K, Hokanson JE, Kinney GL, Snell-Bergeon JK, Heinecke JW, Bornfeldt KE. Increased apolipoprotein C3 drives cardiovascular risk in type 1 diabetes. J Clin Invest. 2019 07 11; 129(10):4165-4179.
-
Crosby J, Peloso GM, Auer PL, Crosslin DR, Stitziel NO, Lange LA, Lu Y, Tang ZZ, Zhang H, Hindy G, Masca N, Stirrups K, Kanoni S, Do R, Jun G, Hu Y, Kang HM, Xue C, Goel A, Farrall M, Duga S, Merlini PA, Asselta R, Girelli D, Olivieri O, Martinelli N, Yin W, Reilly D, Speliotes E, Fox CS, Hveem K, Holmen OL, Nikpay M, Farlow DN, Assimes TL, Franceschini N, Robinson J, North KE, Martin LW, DePristo M, Gupta N, Escher SA, Jansson JH, Van Zuydam N, Palmer CN, Wareham N, Koch W, Meitinger T, Peters A, Lieb W, Erbel R, Konig IR, Kruppa J, Degenhardt F, Gottesman O, Bottinger EP, O'Donnell CJ, Psaty BM, Ballantyne CM, Abecasis G, Ordovas JM, Melander O, Watkins H, Orho-Melander M, Ardissino D, Loos RJ, McPherson R, Willer CJ, Erdmann J, Hall AS, Samani NJ, Deloukas P, Schunkert H, Wilson JG, Kooperberg C, Rich SS, Tracy RP, Lin DY, Altshuler D, Gabriel S, Nickerson DA, Jarvik GP, Cupples LA, Reiner AP, Boerwinkle E, Kathiresan S. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014 Jul 03; 371(1):22-31.
-
Walker RW, Sinatra F, Hartiala J, Weigensberg M, Spruijt-Metz D, Alderete TL, Goran MI, Allayee H. Genetic and clinical markers of elevated liver fat content in overweight and obese Hispanic children. Obesity (Silver Spring). 2013 Dec; 21(12):E790-7.
-
Harvey SB, Zhang Y, Wilson-Grady J, Monkkonen T, Nelsestuen GL, Kasthuri RS, Verneris MR, Lund TC, Ely EW, Bernard GR, Zeisler H, Homoncik M, Jilma B, Swan T, Kellogg TA. O-glycoside biomarker of apolipoprotein C3: responsiveness to obesity, bariatric surgery, and therapy with metformin, to chronic or severe liver disease and to mortality in severe sepsis and graft vs host disease. J Proteome Res. 2009 Feb; 8(2):603-12.
-
Kasthuri RS, Verneris MR, Ibrahim HN, Jilma B, Nelsestuen GL. Studying multiple protein profiles over time to assess biomarker validity. Expert Rev Proteomics. 2006 Aug; 3(4):455-64.
-
Hokanson JE, Kinney GL, Cheng S, Erlich HA, Kretowski A, Rewers M. Susceptibility to type 1 diabetes is associated with ApoCIII gene haplotypes. Diabetes. 2006 Mar; 55(3):834-8.
-
Hayden MR, Kirk H, Clark C, Frohlich J, Rabkin S, McLeod R, Hewitt J. DNA polymorphisms in and around the Apo-A1-CIII genes and genetic hyperlipidemias. Am J Hum Genet. 1987 May; 40(5):421-30.
-
Falko JM, Schonfeld G, Witztum JL, Kolar JB, Salmon P. Effects of short-term high carbohydrate, fat-free diet on plasma levels of Apo C-II and Apo C-III and on the Apo C subspecies in human plasma lipoproteins. Metabolism. 1980 Jul; 29(7):654-61.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|